CAR-T Therapy: Working with a Manufacturing Partner
Summary: The highly complex logistics of autologous and allogeneic CAR-T cell therapies coupled with the characteristics of the biological blueprint of donor and patient sourced material, necessitate consideration of numerous critical factors when it comes to scaling manufacturing and working with a suitable manufacturing partner. Much effort is underway across manufacturing partners to improve the processes, scale, timelines, and production pipelines for CAR-T therapies. Nevertheless, there remain many difficult challenges in scaling up autologous and allogenic CAR-T cell manufacturing and characterizing the function and potency of CAR-T cell products. In this roundtable — CAR-T Therapy: Working with a Manufacturing Partner — hear from four distinguished experts as they critically weigh the benefits of working with a manufacturing partner. This roundtable, sponsored by Catalent, is a must-watch for early and late-stage cell therapy innovator companies who are considering a manufacturing partnership.